Search 

AlephBot is developing a new paradigm in healthcare, the procedure monitor.
The solution helps medical teams maximize treatment efficiency during and after medical procedures (e.g., resuscitation, labor, general anesthesia). It provides the team members with valuable real-time information that is adaptive to their actions and to the procedure’s stage, even if they are under pressure or can’t recall procedure steps by heart. AlephBot also automatically documents the medical procedure, which serves for both medical education and medico-legal purposes.

** AlephBot uniqueness **
We capture the human perspective of a procedure by analyzing the relevant info from the on-going structural medical conversation. We add this layer to the data collected from other sources.
Therefore, we gain higher accuracy of the analyzed medical situation, which enables us to identify the procedure stage and provide meaningful info, in real-time.

** Status **
AlephBot is developing its core technology. The company, pre-seed funded, was selected to the DRIVE accelerator at the Technion (Israel institute of Technology), and received grants from the Israel Innovation Authority.
AlephBot cooperates with big and small hospitals from day one. This serves our intention to increase treatment efficiency both in mega-hospitals in big cities and in smaller ones in the periphery and rural areas.

AlephBot is active in its target markets (Germany, France, Italy and the US) and won several national and international (France, Germany, Denmark) events and competitions. The company is still not active in China - an opportunity!

** Next steps **
We are currently looking for seed investment to finalize our core technology development and bring the product to clinical trial stage in two years. Sales are planned in three years, post regulation clearance.

Alignment Ventures is a seed stage life science venture fund with heavy operational emphasis. We typically spin companies out of University technology and serve as the Founding CEO until we can hit sufficient milestones to raise a Series A financing. In this fashion, Partner, Michael Tippie was CEO of TomegaVax until 2016 when that company was acquired by Vir Biotechnology. Vir is now a $4 BB+ public company.

Allakos is a public-traded clinical-stage biopharmaceutical company developing first-in-class antibody-based therapeutics to treat allergic and inflammatory diseases.

Allegro 3D is an emerging 3D printing and bioprinting company located in San Diego, a world hub for biotechnology. At the convergence of advanced additive manufacturing, stem cell biology and biomaterials, Allegro 3D’s expertise in bioprinting and biomaterials enables high-throughput manufacturing of advanced biomedical devices, cell matrices and precision human tissues for cell culture, drug screening, therapeutics and regenerative medicine.

Using the world’s most advanced bioprinting technologies developed at the University of California San Diego, Allegro 3D is poised to provide customers with transformational biofabrication solutions that will revolutionize healthcare innovations related to regenerative medicine, drug discovery, and biomedical research.

Clinical stage Biopharma

invest

MNC pharmaceuticals company

Founded in 2009 by Marc Andreessen and Ben Horowitz, Andreessen Horowitz (known as "a16z") is a venture capital firm in Silicon Valley, California, that backs bold entrepreneurs building the future through technology. We are stage agnostic: We invest in seed to late-stage technology companies, across the consumer, enterprise, bio/healthcare, crypto, and fintech spaces. a16z has nearly $16.5B in assets under management across multiple funds, including the $1.4B Bio funds, the $865M Crypto funds, and the Cultural Leadership Fund.

a16z is defined by respect for the entrepreneur and the entrepreneurial company building process; we know what it’s like to be in the founder’s shoes. The firm is led by general partners, many of whom are former founders/operators, CEOs, or CTOs of successful technology companies, and who have domain expertise ranging from biology to crypto to distributed systems to security to marketplaces to financial services.

We aim to connect entrepreneurs, investors, executives, engineers, academics, industry experts, and others in the technology ecosystem. We have built a network of experts including technical and executive talent; top media and marketing resources; Fortune 500/Global 2000 companies; as well as other technology decision makers, influencers, and key opinion leaders. a16z uses this network as part of our commitment to help our portfolio companies grow their business, so our operating teams provide entrepreneurs with access to expertise and insights across the entire spectrum of company building.